| Days after vaccination:||3
|Vaccination / Manufacturer
||Lot / Dose
||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH
||ER2613 / 1
||- / SYR
Administered by: Public Purchased by: ?
Symptoms: CSF protein increased,
Lumbar puncture abnormal,
Magnetic resonance imaging head,
Magnetic resonance imaging spinal,
SMQs:, Rhabdomyolysis/myopathy (broad), Peripheral neuropathy (broad), Oropharyngeal conditions (excl neoplasms, infections and allergies) (narrow), Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Hearing impairment (broad)
Life Threatening? Yes
Birth Defect? No
Permanent Disability? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 2 days
Extended hospital stay? No
Other Medications: Sertraline (Zoloft) 200mg Norethindrone-Estradiol-Iron (1.5/30, 28, oral)
Current Illness: Patient reported slight post-nasal drift and the "sniffles" 2 weeks prior to receiving the vaccine that only lasted a few days.
Preexisting Conditions: Anxiety, Migraines
Diagnostic Lab Data: A lumbar puncture (to collect CSF) and brain MRI and total spine were done.
CDC Split Type:
Write-up: 3 days after receiving the Pfizer COVID-19 vaccination, the patient reported numbness in her bilateral toes that progressed to numbness and weakness of her bilateral legs. 5 days after the onset of her initial symptoms, the patient noted bilateral numbness in her fingers and her mouth, that also progressed to weakness in her bilateral arms. A few days later, the patient noticed a right-sided facial droop that brought her to the ED. Given the patient''s symptoms and elevated protein in the patient''s CSF (obtained via lumbar puncture), the patient''s symptoms are concerning for Guillain-Barre syndrome. The patient was started today on 5 days of immune globulin (PRIVIGEN) 10 % IV infusion 25 g.